Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Importance The clinical benefits of novel treatments for moderate to severe psoriasis are
well established, but wide variations exist in patient response across different therapies. In …

Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …

Psoriasis is a complex inflammatory process resulting from activation of the well-defined
interleukin (IL)-23/T17 cytokine axis. We review the role of key cytokines IL-17 and IL-23 in …

Psoriasis is a common inflammatory skin disease involving interactions between
keratinocytes and immune cells that significantly affects the quality of life. It is characterized …

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin
and joint manifestations affecting approximately 2% of the population. In this first of 5 …

Background Biologic agents offer a range of new therapeutic options for patients with
psoriasis; however, the relative benefit–risk profiles of such therapies are not well known …

Introduction New generation biologics, including interleukin (IL)-17 and IL-23 inhibitors,
have delivered higher rates of skin clearance than older treatments in head-to-head studies …

During the past 30 years, elucidation of the pathogenesis of rheumatoid arthritis, Crohn's
disease, psoriasis, psoriatic arthritis and ankylosing spondylitis at the cellular and molecular …